Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Jump To

Harvoni Dosage

Generic name: ledipasvir and sofosbuvir
Drug class: Antiviral combinations

Medically reviewed by  A Ras MD.

 

Recommended Adult Dosing

Dosage forms:  TAB: 45 mg/200 mg, 90 mg/400 mg; PELLET: 45 mg/200 mg per pkt

Hepatitis C infection, chronic

[genotype 1, tx-naive pts]
Dose: 90 mg/400 mg PO qd x12wk; Info: may consider 8wk tx duration in non-HIV infected pts w/o cirrhosis and w/ pre-tx HCV RNA levels <6 million units/mL; give w/ ribavirin in pts w/ decompensated cirrhosis or liver transplant hx; refer to AASLD/IDSA hepatitis C guidelines; do not chew pellets
[genotype 1, tx-experienced pts]
Dose: 90 mg/400 mg PO qd x12wk; Info: may give w/ ribavirin; may give x24wk in pts w/ decompensated cirrhosis; refer to AASLD/IDSA hepatitis C guidelines; do not chew pellets
[genotype 4]
Dose: 90 mg/400 mg PO qd x12wk; Info: may give w/ ribavirin x12wk or x24wk; may give x24wk in pts w/ decompensated cirrhosis; refer to AASLD/IDSA hepatitis C guidelines; do not chew pellets
[genotypes 5 or 6]
Dose: 90 mg/400 mg PO qd x12wk; Info: for pts w/ or w/o compensated cirrhosis; give w/ ribavirin in pts w/ liver transplant hx; may give x24wk in pts w/ decompensated cirrhosis; refer to AASLD/IDSA hepatitis C guidelines; do not chew pellets

Renal dosing

[pts w/ decompensated cirrhosis]
mild-moderate impairment: no adjustment; severe impairment: not defined
HD/PD: not defined
[all other pts]
renal impairment: no adjustment
HD/PD: no adjustment; no supplement

Hepatic dosing

[no adjustment]

Recommended Peds Dosing

Dosage forms:  TAB: 45 mg/200 mg, 90 mg/400 mg; PELLET: 33.75 mg/150 mg per pkt, 45 mg/200 mg per pkt

Chronic hepatitis C infection, genotype 1

[tx-naive pts, 3 yo and older, <17 kg]
Dose: 33.75 mg/150 mg PO qd x12wk; Info: for pts w/o cirrhosis or w/ compensated cirrhosis; refer to AASLD/IDSA hepatitis C guidelines; do not chew pellets
[tx-naive pts, 3 yo and older, 17-34 kg]
Dose: 45 mg/200 mg PO qd x12wk; Info: for pts w/o cirrhosis or w/ compensated cirrhosis; refer to AASLD/IDSA hepatitis C guidelines; do not chew pellets
[tx-naive pts, 3 yo and older, >35 kg]
Dose: 90 mg/400 mg PO qd x12wk; Info: for pts w/o cirrhosis or w/ compensated cirrhosis; refer to AASLD/IDSA hepatitis C guidelines; do not chew pellets
[tx-experienced pts, 3 yo and older, <17 kg]
Dose: 33.75 mg/150 mg PO qd x12wk; Info: give x24 wk in pts w/ compensated cirrhosis; refer to AASLD/IDSA hepatitis C guidelines; do not chew pellets
[tx-experienced pts, 3 yo and older, 17-34 kg]
Dose: 45 mg/200 mg PO qd x12wk; Info: give x24 wk in pts w/ compensated cirrhosis; refer to AASLD/IDSA hepatitis C guidelines; do not chew pellets
[tx-experienced pts, 3 yo and older, >35 kg]
Dose: 90 mg/400 mg PO qd x12wk; Info: give x24 wk in pts w/ compensated cirrhosis; refer to AASLD/IDSA hepatitis C guidelines; do not chew pellets

Chronic hepatitis C infection, genotypes 4, 5, or 6

[3 yo and older, <17 kg]
Dose: 33.75 mg/150 mg PO qd x12wk; Info: for pts w/o cirrhosis or w/ compensated cirrhosis; refer to AASLD/IDSA hepatitis C guidelines; do not chew pellets
[3 yo and older, 17-34 kg]
Dose: 45 mg/200 mg PO qd x12wk; Info: for pts w/o cirrhosis or w/ compensated cirrhosis; refer to AASLD/IDSA hepatitis C guidelines; do not chew pellets
[3 yo and older, >35 kg]
Dose: 90 mg/400 mg PO qd x12wk; Info: for pts w/o cirrhosis or w/ compensated cirrhosis; refer to AASLD/IDSA hepatitis C guidelines; do not chew pellets

Renal dosing

[not defined]
renal impairment: consider adult renal dosing for guidance
HD/PD: consider adult renal dosing for guidance

Hepatic dosing

[no adjustment]

 

SRC: NLM .

Read Next Article